Triple
T23399618
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | bapineuzumab |
E559467
|
entity |
| Predicate | target |
P860
|
FINISHED |
| Object |
beta-amyloid
Beta-amyloid is a peptide that accumulates abnormally in the brain to form plaques strongly associated with the development and progression of Alzheimer’s disease.
|
E1583704
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: beta-amyloid | Statement: [bapineuzumab, target, beta-amyloid]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: beta-amyloid Context triple: [bapineuzumab, target, beta-amyloid]
-
A.
alpha-synuclein
Alpha-synuclein is a neuronal protein whose abnormal aggregation is a hallmark of Parkinson’s disease and related synucleinopathies.
-
B.
Lewy bodies
Lewy bodies are abnormal aggregates of the protein alpha-synuclein that accumulate inside neurons and are characteristic of Parkinson’s disease and related neurodegenerative disorders.
-
C.
Alzheimer
Alzheimer is a German surname most famously associated with Alois Alzheimer, the neurologist after whom Alzheimer’s disease is named.
-
D.
bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
-
E.
Alzheimer's disease
Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, and is the most common cause of dementia in older adults.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: beta-amyloid Triple: [bapineuzumab, target, beta-amyloid]
Generated description
Beta-amyloid is a peptide that accumulates abnormally in the brain to form plaques strongly associated with the development and progression of Alzheimer’s disease.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: beta-amyloid Target entity description: Beta-amyloid is a peptide that accumulates abnormally in the brain to form plaques strongly associated with the development and progression of Alzheimer’s disease.
-
A.
alpha-synuclein
Alpha-synuclein is a neuronal protein whose abnormal aggregation is a hallmark of Parkinson’s disease and related synucleinopathies.
-
B.
Lewy bodies
Lewy bodies are abnormal aggregates of the protein alpha-synuclein that accumulate inside neurons and are characteristic of Parkinson’s disease and related neurodegenerative disorders.
-
C.
Alzheimer
Alzheimer is a German surname most famously associated with Alois Alzheimer, the neurologist after whom Alzheimer’s disease is named.
-
D.
bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
-
E.
Alzheimer's disease
Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, and is the most common cause of dementia in older adults.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e24549610c8190a069d6411ce5f661 |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1a4dedfcc8190ab93cec3c3d15c53 |
completed | April 29, 2026, 6:27 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a0c5df194bc819084aa4de85966c68f |
completed | May 19, 2026, 12:56 p.m. |
| NEDg | Description generation | batch_6a0c5f52fe308190b87c53f9a9d915e0 |
completed | May 19, 2026, 1:02 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0c5ffbea40819088a5a01a3763c718 |
completed | May 19, 2026, 1:05 p.m. |
Created at: April 17, 2026, 5:37 p.m.